Skip to main content
. Author manuscript; available in PMC: 2010 Dec 8.
Published in final edited form as: J Nucl Med. 2010 Jul 21;51(8):1293–1300. doi: 10.2967/jnumed.110.076174

Figure 3.

Figure 3

Bar chart showing selected tissue biodistribution data (%ID/g) for uptake of either high- (181.7 ± 1.1 MBq/mg [4.91 ± 0.03 mCi/mg]; 3–4 µg of mAb per mouse) or low-specific-activity (60-fold decrease, 3.04 MBq/mg [0.082 mCi/mg]; 300 µg of mAb per mouse) formulations of 89Zr-DFO-J591 (0.55–0.74 MBq [15–20 µCi], in 200 µL of sterile saline for injection) in male athymic nu/nu mice bearing subcutaneous LNCaP (PSMA-positive) or PC-3 (PSMA-negative) tumors.

HHS Vulnerability Disclosure